Piper Jaffray Upgrades United Therapeutics (UTHR) to Neutral, Sees Limited Downside
Tweet Send to a Friend
Piper Jaffray & Co. upgrades United Therapeutics (Nasdaq: UTHR) from Sell to Neutral. Price target reduced from $71 to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
